~Aderans Industry-Academia Collaboration~ Aderans co-sponsored a seminar at the 11th Cancer/Inflammation and Antioxidant Study Group (CIA Study Group)

Presentation of research to prevent hair loss in anticancer drug treatment

Aderans Co., Ltd. Aderans Co., Ltd., a global wellness business for hair, beauty, and health (Headquarters: Shinjuku-ku, Tokyo; Representative Director: Yoshihiro Tsumura) co-sponsored a sponsored seminar sponsored by Aderans at the Cancer/Inflammation and Antioxidant Research Group (CIA Research Group/Period: Saturday, November 27, 2021) held via web distribution. At the seminar co-sponsored by Aderans, Dr. Kanae Tarino, Assistant Professor, Department of Breast Surgery, Department of Surgery, Showa University School of Medicine, and Dr. Yohei Kono, Assistant Professor, Advanced Critical Care Center, Department of Gastroenterological and Pediatric Surgery, Oita University School of Medicine, who is promoting joint research with Aderans, gave a lecture. Also, Professor Masafumi Inomata, Department of Gastroenterology and Pediatric Surgery, Oita University School of Medicine, acted as moderator. The Cancer/Inflammation and Antioxidant Research Group (CIA Research Group) is led by Oita University and is headed by Oita University President Seigo Kitano, who is a world authority on endoscopic treatment, and has achieved top-class research results in this field. It is a medical research society in which the universities, hospitals, and companies that own it participate. We are promoting research on various themes related to cancer and inflammation with the aim of elucidating the pathology and developing new treatment methods from the viewpoint of "antioxidation", which is a fundamental phenomenon of living organisms. This 11th meeting will be held as a web distribution in consideration of the recent spread of infection, and it will be the 6th time that Aderans will co-sponsor this study group. As the mission of a leading company in total hair solutions, Aderans aims to develop "the best products", which is one of its management philosophies, and to develop the hair-related industry. We are actively working on hair-related research through industry-academia collaboration, such as scalp care-related research and anti-cancer drug hair loss control research. Disseminating the results of industry-university joint research through academic societies in Japan and overseas, and having researchers around the world present their research results will lead to further progress in the hair industry and contribute to the resolution of many people's hair concerns. We believe that it is our CSR (Corporate Social Responsibility).

From the left, the moderators, Professor Inomata, Professor Taruno, and Professor Kono *Remote presentations

Aderans Sponsored Seminar Lecture Outline Moderator Professor Masafumi Inomata, Professor, Department of Gastroenterology and Pediatric Surgery, Oita University School of Medicine Subject 1Presenter Assistant Professor, Division of Breast Surgery, Department of Surgery, Showa University School of Medicine Dr. Kanae Taruno Title Efforts to prevent chemotherapy-induced alopecia (CIA) in breast cancer perioperative chemotherapy Lecture content Chemotherapy-induced alopecia ( CIA) causes a great deal of psychological distress to patients and does not directly affect their lives or daily activities, but it is a more serious side effect for patients than medical professionals think. Among them, standard perioperative chemotherapy for breast cancer causes 100% hair loss, and it is a factor that influences treatment selection due to the psychological burden on breast cancer patients. In addition, it takes time for the hair to re-grow not only during chemotherapy, but also afterwards, until it returns to the state before treatment. There are also reports of therapy-induced permanent hair loss (pCIA), which is a side effect that greatly affects not only treatment but also long-term QOL after treatment. A device (Paxman scalp cooling system), which aims to suppress hair loss associated with chemotherapy by cooling the scalp surface and reducing scalp blood flow during chemotherapy, has been reported to have a hair loss suppression effect. Approved as a medical device in March 2013. We report a case in which a scalp cooling device was used during perioperative chemotherapy for breast cancer at our hospital. A synergistic effect is expected from the combined use of a scalp cooling device and lotion containing an α-lipoic acid derivative. Topic 2 PresenterDr. Yohei Kono, Assistant Professor, Advanced Critical Care Center, Department of Gastroenterological and Pediatric Surgery, Oita University School of Medicine Lecture content [Introduction] Appearance changes such as hair loss, dermatitis, and wounds caused by cancer treatments such as surgery, chemotherapy, and radiation therapy have a significant impact on the mental and QOL of cancer patients. . In recent years, care for appearance symptoms (look care) has come to be emphasized, and the current situation and problems are becoming clear. Among them, anticancer drug alopecia is a side effect that frequently occurs in chemotherapy for various malignant diseases including breast cancer, but there is still no sufficient countermeasure. As an industry-academia collaborative research and development project, we have been working on anti-cancer hair loss measures, and we will introduce the details of the project. [Project research contents] 1. Basic research to elucidate the mechanism of anti-cancer drug hair loss. It has been shown to be one of the factors of hair loss pathology. 2. Research and development of a hair loss prevention method using an antioxidant α-lipoic acid derivative. Dermal administration was performed. Administration of 1% α-lipoic acid derivative inhibited hair loss, and histopathological examination showed that inflammatory cell infiltration and destruction of hair roots and hair shafts were alleviated. 3. A clinical study to examine the effects of α-lipoic acid derivatives on anticancer drug hair loss A multicenter joint study was conducted on 100 breast cancer patients undergoing postoperative adjuvant chemotherapy, and the effects of applying lotion containing α-lipoic acid derivatives to the scalp were examined. . Although it was not possible to show a hair loss prevention effect, it showed an effect of shortening the hair loss period. 4. Through an industry-academia collaborative project with a leading hair-related company, we have commercialized an α-lipoic acid derivative-containing scalp lotion based on anticancer drug hair loss research. [Future prospects for efforts to prevent hair loss with anticancer drugs] In this project, further research is progressing, such as the application of α-lipoic acid derivatives to patients with gastrointestinal cancer and combined use with scalp cooling. In recent years, cancer patients' attitudes toward appearance problems have changed significantly, and it is desired to revitalize research and development aimed at improving the QOL of patients. Society Overview Society Name: The 11th Cancer, Inflammation and Antioxidant Study Group (CIA Study Group) Tutor: Toshikatsu Hanada, Professor, Department of Cell Biology, Faculty of Medicine, Oita University Date: Saturday, November 27, 2021 Venue: Web Held

This press release contains information for members of the media.

If you register as a media user, you can view various special information such as contact information for company representatives and information on events and press conferences. *The content varies depending on the press release.